Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Merit L Goodman"'
Autor:
Alfredo A Molinolo, Junping Wei, Xiao-Yi Yang, Gangjun Lei, Zachary C Hartman, Lauryn R Werner, Katelin A Gibson, Merit L Goodman, Dominika E Helm, Katherine R Walter, Sean M Holloran, Gloria M Trinca, Richard C Hastings, Howard H Yang, Rashna Madan, Mary A Markiewicz, Prabhakar Chalise, Margaret L Axelrod, Justin M Balko, Kent W Hunter, Carol A Lange, Christy R Hagan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Clinical studies have linked usage of progestins (synthetic progesterone [P4]) to breast cancer risk. However, little is understood regarding the role of native P4, signaling through the progesterone receptor (PR), in breast tumor formatio
Externí odkaz:
https://doaj.org/article/3ebc51e37c9e47cf891b9468adc3f631
Autor:
Bruce F. Kimler, Prabhakar Chalise, Devin C. Koestler, Byron J. Gajewski, Merit L. Goodman, Christy R. Hagan, Carola M. Zalles, Onalisa Winblad, Trina Metheny, Teresa A. Phillips, Amy L. Kreutzjans, Jennifer L. Nydegger, Kandy R. Powers, Lauren Nye, Carol J. Fabian
Supplementary Tables 1-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::195da0af0d00bf4b8dcd6e8ed7753740
https://doi.org/10.1158/1940-6207.22534667.v1
https://doi.org/10.1158/1940-6207.22534667.v1
Autor:
Christy R. Hagan, Geoffrey L. Greene, Victor X. Jin, Katelin A. Gibson, Gloria M. Trinca, Sean M. Holloran, Tianbao Li, Jade A. Hall, Hari Singhal, Merit L. Goodman, Katherine R. Walter
Supplemental Figure 1: PR represses ISGs in multiple cell line models. Supplemental Figure 2: ISG repression is PR-dependent. Supplemental Figure 3. ISG repression not observed in PR-negative breast cancer cell lines. Supplemental Figure 4. PR is rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37938223f28675a8a5b484aed6072a54
https://doi.org/10.1158/1541-7786.22516108.v1
https://doi.org/10.1158/1541-7786.22516108.v1
Autor:
Bruce F. Kimler, Prabhakar Chalise, Devin C. Koestler, Byron J. Gajewski, Merit L. Goodman, Christy R. Hagan, Carola M. Zalles, Onalisa Winblad, Trina Metheny, Teresa A. Phillips, Amy L. Kreutzjans, Jennifer L. Nydegger, Kandy R. Powers, Lauren Nye, Carol J. Fabian
Interventions that relieve vasomotor symptoms while reducing risk for breast cancer would likely improve uptake of chemoprevention for perimenopausal and postmenopausal women. We conducted a pilot study with 6 months of the tissue selective estrogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fa5fe4312a09ebc469106c80f9c6d93
https://doi.org/10.1158/1940-6207.c.6547601.v1
https://doi.org/10.1158/1940-6207.c.6547601.v1
Autor:
Christy R. Hagan, Geoffrey L. Greene, Victor X. Jin, Katelin A. Gibson, Gloria M. Trinca, Sean M. Holloran, Tianbao Li, Jade A. Hall, Hari Singhal, Merit L. Goodman, Katherine R. Walter
The progesterone receptor (PR) regulates transcriptional programs that drive proliferation, survival, and stem cell phenotypes. Although the role of native progesterone in the development of breast cancer remains controversial, PR clearly alters the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09483487cdc120b68d0ed6ca7874b6cd
https://doi.org/10.1158/1541-7786.c.6541282
https://doi.org/10.1158/1541-7786.c.6541282
Autor:
Bruce F. Kimler, Teresa A. Phillips, Carol J. Fabian, Prabhakar Chalise, Lauren Nye, Merit L. Goodman, Carola M. Zalles, Byron J. Gajewski, Devin C. Koestler, Christy R. Hagan, Onalisa Winblad
Publikováno v:
Cancer Research. 80:PD3-06
Agents which both reduce risk for development of breast cancer and relieve vasomotor symptoms are likely to have good uptake and adherence. We conducted a pilot study with 6 months of the tissue selective estrogen complex bazedoxifene (20 mg) and con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bfcb3f2b78d4aba1b88198f02fcd82e
https://doi.org/10.1158/1538-7445.sabcs19-pd3-06
https://doi.org/10.1158/1538-7445.sabcs19-pd3-06
Autor:
Lauryn Rose Werner, Katelin A. Gibson, Merit L. Goodman, Dominika E. Helm, Katherine R. Walter, Sean M. Holloran, Gloria M. Trinca, Richard C. Hastings, Howard H. Yang, Ying Hu, Junping Wei, Gangjun Lei, Xiao-Yi Yang, Rashna Madan, Alfredo A. Molinolo, Mary A. Markiewicz, Prabhakar Chalise, Margaret L. Axelrod, Justin M. Balko, Kent W. Hunter, Zachary C. Hartman, Carol A. Lange, Christy R. Hagan
Publikováno v:
Cancer Research. 82:1351-1351
Clinical studies have linked usage of progestins (synthetic progesterone) to breast cancer risk. However, little is understood regarding the role of native progesterone (P4), signaling through the progesterone receptor (PR), in breast tumor formation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::504be6dfae62c85d0d1f972d24a3c970
https://doi.org/10.1158/1538-7445.am2022-1351
https://doi.org/10.1158/1538-7445.am2022-1351
Autor:
Sean M. Holloran, Kent W. Hunter, Katherine R. Walter, Prabhakar Chalise, Zachary C. Hartman, Mary A. Markiewicz, Xiao Yi Yang, Alfredo A. Molinolo, Carol A. Lange, Howard H. Yang, Margaret L Axelrod, Gangjun Lei, Gloria M. Trinca, Katelin A. Gibson, Justin M. Balko, Merit L. Goodman, Ying Hu, Dominika E. Helm, Richard C. Hastings, Lauryn R. Werner, Rashna Madan, Junping Wei, Christy R. Hagan
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
BackgroundClinical studies have linked usage of progestins (synthetic progesterone [P4]) to breast cancer risk. However, little is understood regarding the role of native P4, signaling through the progesterone receptor (PR), in breast tumor formation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ed4faa99edb666c17c6a1f8b9e76401
https://pubmed.ncbi.nlm.nih.gov/33958486
https://pubmed.ncbi.nlm.nih.gov/33958486
Autor:
Lauryn R Werner, Katelin A Gibson, Merit L Goodman, Dominika E Helm, Katherine R Walter, Sean M Holloran, Gloria M Trinca, Richard C Hastings, Howard H Yang, Ying Hu, Junping Wei, Gangjun Lei, Xiao-Yi Yang, Rashna Madan, Alfred A Molinolo, Mary A Markiewicz, Prabhakar Chalise, Margaret L Axelrod, Justin M Balko, Kent W Hunter, Zachary C Hartman, Carol A Lange, Christy R Hagan
Publikováno v:
Cancer Research. 82:P4-04
Clinical studies have linked usage of progestins (synthetic progesterone) to breast cancer risk. However, little is understood regarding the role of native progesterone (P4), signaling through the progesterone receptor (PR), in breast tumor formation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88158d4c53e40334142a98fd6cac858f
https://doi.org/10.1158/1538-7445.sabcs21-p4-04-07
https://doi.org/10.1158/1538-7445.sabcs21-p4-04-07
Autor:
Merit L. Goodman, Chad Slawson, Prabhakar Chalise, Christy R. Hagan, Rashna Madan, Gloria M. Trinca, Clive D'Santos, Evangelia K. Papachristou
Publikováno v:
Hormones and Cancer. 9:12-21
Emerging clinical trial data implicate progestins in the development of breast cancer. While the role for the progesterone receptor (PR) in this process remains controversial, it is clear that PR, a steroid-activated nuclear receptor, alters the tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34e1dd5f34687825f252e83b4e876da5
https://doi.org/10.1007/s12672-017-0310-9
https://doi.org/10.1007/s12672-017-0310-9